Celgene ([[CELG]] -1%) and suitor Bristol-Myers Squibb ([[BMY]] -1%) are experiencing somewhat wider trading ranges as investors react to the latest rumors
Biotech M&A is on a roll in 2019, with a couple of multi-billion dollar deals announced already, including Bristol-Myers Squibb Co (NYSE: BMY)'s proposed buy of Celgene...
By Svea Herbst-Bayliss and Greg Roumeliotis (Reuters) - Bristol-Myers Squibb (NYSE:BMY) Co said on Wednesday that activist hedge fund Starboard Value LP intends to nominate five...
Merck & Co. Inc. (NYSE:MRK) announced that it will acquire late-stage immunotherapy company Immune Design (NASDAQ:IMDZ) for $300 million in cash. Per the deal, Merck...
Bausch Health Companies Inc. (NYSE:BHC) reported better-than-expected results for the fourth quarter of 2018. The company’s adjusted earnings per share of $1.05 beat the...
Novo Nordisk (CO:NOVOb) A/S (NYSE:NVO) announced that the FDA has approved its biologics license application (BLA) for Esperoct (turoctocog alfa pegol, N8-GP) regarding the...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Strong Buy||Strong Buy||Neutral||BUY||Strong Sell|
|Summary||Strong Buy||Strong Buy||Neutral||Buy||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Inside Up||30||1||Feb 22, 2019 03:00PM|
|Engulfing Bearish||30||3||Feb 22, 2019 02:00PM|
|Three Outside Up||15||3||Feb 22, 2019 03:00PM|
|Petroleo Brasileiro Petrobras ADR||16.63||16.75||16.53||-0.02||-0.12%||11.55M||22/02|
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||$250||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.